Genentech
| Company type | Subsidiary |
|---|---|
| Nasdaq: DNA | |
| Industry | Biotechnology |
| Founded | 1976 |
| Founders | |
| Headquarters | South San Francisco, California, United States |
Key people |
|
| Products | Avastin, Herceptin, Rituxan, Perjeta, Kadcyla, Gazyva, Tarceva, Ocrevus, Polivy, Tecentriq, Xofluza, Hemlibra, Venclexta, Esbriet, Cotellic, Alecensa, Zelboraf, Nutropin, Actemra, Lucentis, Xolair, Activase, Cathflo Activase, Xeloda, Boniva, TNKase, CellCept, Pegasys, Pulmozyme, Tamiflu, Valcyte, Anaprox, Cytovene, EC-Naprosyn, Erivedge, Fuzeon, Invirase, Klonopin, Kytril, Naprosyn, Rocephin, Roferon-A, Romazicon, Valium, Xenical, Zenapax |
| Revenue | $26.4 billion (2020) |
Number of employees | 11,900 (2025) |
| Parent | Roche |
| Website | www |
| Footnotes / references | |
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It operates as an independent subsidiary of holding company Roche. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.
As of July 2021, Genentech employed 13,539 people.